SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending after its Q4 earnings showcased explosive revenue and ARR growth with positive adjusted EBITDA, complemented by the strategic acquisition of AI agent search company Tavily. Despite a revenue and EPS miss against analyst estimates, the community is debating strong operational execution and robust 2026 guidance signaling long-term potential in the AI infrastructure market.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as its oral obesity drug, VK2735, will advance directly into Phase 3 trials, significantly accelerating its market timeline. This news has intensified community discussion around its "best-in-class" potential and the increased likelihood of a major partnership or acquisition, particularly given the large short interest and the vast, competitive weight loss drug market.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is trending on the heels of Nuclearelectrica's approval for the Doiceti SMR project and a new partnership with Oak Ridge National Laboratory for AI-enabled nuclear fuel management. The community is actively discussing its potential to address the massive energy demands of AI data centers, with many seeing it as a key player in the global shift towards small modular reactors, despite ongoing debates about its valuation and project timelines.

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

NovoCure Ltd

Novocure is trending due to the FDA approval of its Optune Pax device for locally advanced pancreatic cancer, hailed as the first new treatment in decades for this aggressive disease, sparking widespread discussion about its potential market impact and prompting both bullish speculation and cautionary outlooks from the community.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is trending due to a significant earnings beat and strong guidance, which included accelerating revenue, record profitability, and positive free cash flow. The community is actively discussing the company's turnaround, potential for a short squeeze, and the increasing role of AI agent traffic and enhanced security offerings as key growth catalysts.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending due to significant aftermarket volatility following its proposed $1 billion convertible notes offering, which emerged shortly after the successful unfolding of its BlueBird 6 satellite and inclusion in the MSCI World Index. The community is debating whether this financial move provides crucial capital for accelerating constellation deployment, AI opportunities, and government contracts, or signals further dilution for a pre-revenue company.

Crocs, Inc. engages in the design, development, manufacture, worldwide marketing, sale, and distribution of lifestyle footwear and accessories. It operates through the Crocs Brand and HEYDUDE Brand segments. The company was founded by Scott Seamans, George B. Boedecker, Jr., and Lyndon V. Hanson III in 2002 and is headquartered in Broomfield, CO.

Crocs Inc

Crocs is trending upward after reporting a strong Q4 earnings beat and providing an optimistic outlook for Q1 and fiscal year 2026, driven by robust direct-to-consumer and international sales. The community is celebrating the positive financial results and confident management commentary, particularly regarding planned cost savings and sustained brand strength.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is trending following an earnings report where strong AI infrastructure demand drove revenue and EPS beats, alongside raised full-year guidance, but a lower-than-expected gross margin forecast, impacted by rising memory costs, has led to a market pullback. The community is now debating whether the company's significant AI tailwinds will quickly overcome these margin pressures and ongoing competitive challenges.

TOSHI

TOSHI is trending with growing volume, attracting significant community attention as a prominent 'blue cat' meme coin on the Base ecosystem. The community is actively discussing its potential for a major rally and breakout, positioning it as a key player amidst broader crypto market recovery.

HubSpot, Inc. engages in cloud-based customer relationship management. Its platform includes marketing, sales, service, operations and content management system, as well as other tools, integrations and native payment solutions. It operates through the following geographical segments: Americas, Europe and Asia Pacific. The company was founded by Brian Patrick Halligan and Dharmesh Shah on April 4, 2005, and is headquartered in Cambridge, MA.

HubSpot Inc

HubSpot (HUBS) is trending after reporting strong Q4 earnings and optimistic guidance, alongside a share repurchase program, sparking intense debate among investors. Many see a buying opportunity fueled by solid performance and a relatively low valuation, while a skeptical segment questions long-term growth given broader AI disruption concerns and analysts' tempered price targets for the SaaS sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nuwellis Names Carisa Schultz CFO

(RTTNews) - Nuwellis, Inc. (NUWE), a medical technology company, on Friday announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2...

<ul class="summary-bullets"><li>Nuwellis did not disclose the value of the deal that is aimed at expanding the company’s portfolio into real-time renal diagnostics.</li><li>The company said that the transaction is expected to close upon the completion of customary closing conditions.</li><li>The Minneapolis-based company also announced a $5 million private placement and warrant inducement transaction priced at-the-market.</li></ul> Shares of Nuwellis Inc. (NUWE) slumped over 16% after-hours on Thursday after the company said that it has inked an agreement to acquire Israeli medical technology company Rendiatech.Nuwellis did not disclose the value of the deal, which is aimed at expanding the company’s portfolio into real-time renal diagnostics beyond therapeutic fluid management. Rendiatech is focused on automated kidney function monitoring.The company’s current portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions. &nbsp;<h2 class="st-heading-2">Upsides Of The Transaction</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/29/3229142/26106/en/Nuwellis-Enters-into-Definitive-Agreement-to-Acquire-Rendiatech-Advancing-Its-Cardiorenal-Portfolio-Strategy.html">said </a>that the transaction is expected to close upon the completion of customary closing conditions.Upon closing, Nuwellis will gain access to Rendiatech’s Clarity technology, allowing for expansion into advanced urine-based analytics and broader kidney function assessment, the company said, adding that the establishment of new sales channels is not expected to be needed to develop Rendiatech’s technology.“By entering into this transaction, we are positioning the company to extend our capabilities beyond therapeutic fluid removal and into real-time renal monitoring, which we believe is a natural and complementary evolution of our portfolio,” CEO John Erb said.Separately, the Minneapolis-based company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/29/3229143/26106/en/Nuwellis-Announces-5-Million-Private-Placement-and-Warrant-Inducement-Transaction-Priced-At-The-Market.html">announced</a> a $5 million private placement and warrant inducement transaction priced at-the-market. The transaction is expected to close on or about Jan. 30.The company did not detail the purposes for which the proceeds will be used. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NUWE stock stayed at ‘extremely bullish’ territory while message volume stayed at ‘extremely high’ levels.A Stocktwits user said that they are bullish on the acquisition until proven otherwise.<stembedurl>https://www.stocktwits.com/Nuckle_Head/message/643368696</stembedurl><a href="https://stocktwits.com/symbol/NUWE">NUWE stock</a> has dropped over 90% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/spacex-reportedly-considering-merger-with-xai-ahead-of-planned-ipo/cmyilBJR41B">Elon Musk’s SpaceX Reportedly Considering Merger With xAI Ahead Of Planned IPO</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of InMode have fallen nearly 12% over the past 12 months. 

Nuwellis Stock Slips Over 26% After Hours On New Acquisition, $5M Placement Announcement

The company did not disclose the value of the acquisition, which is aimed at expanding the company’s portfolio into real-time renal diagnostics.

Equity

Nuwellis, Inc. Profit Declines In Q3

(RTTNews) - Nuwellis, Inc. (NUWE) announced earnings for third quarter that Dropped, from last year...

Nuwellis shares rose in after-hours trading after the company said it was granted a new U.S. Patent for innovations in blood filtering machine design and methods that improve fluid management accuracy during ultrafiltration therapy.At the close on Tuesday, <a href="https://stocktwits.com/symbol/NUWE">Nuwellis shares</a> dropped 11.7% to $6.9, but surged 31.3% to $9.05 in after-hours trading following news of the patent grant.The patent, titled “Extracorporeal Blood Filtering Machine and Methods”, addresses a critical source of error in continuous renal replacement therapy (CRRT) by factoring in actual fluid density, rather than assuming a standard value.&nbsp;Most current systems use 1 g/mL as&nbsp;the&nbsp;default, which can lead to miscalculations in fluid balance when actual densities differ.&nbsp;The new approach allows machines to adjust calculations based on input, measurement, or derived values, improving volumetric flow tracking and patient care.The company,&nbsp;based in Minneapolis with operations in Ireland,&nbsp;markets the Aquadex SmartFlow system for ultrafiltration and is&nbsp;The patent comes on the heels of two other major corporate developments in recent months.&nbsp;In June, Nuwellis raised $4.3 million through an underwritten public offering that included common stock and warrants. The company said the proceeds would go toward working capital, general corporate purposes, and potential acquisitions.In May, Nuwellis finalized a manufacturing agreement with KDI Precision Manufacturing, transferring assembly responsibilities for its Aquadex SmartFlow console and related products.&nbsp;The partnership&nbsp;aims to expand manufacturing capacity and enhance operational efficiency, with KDI also hiring current Nuwellis assembly employees to ensure a seamless transition.On Stocktwits, retail sentiment for Nuwellis was ‘extremely bullish’ by late Tuesday, improving from the ‘bullish’ mood a day ago, amid ‘extremely high’ message volume.One user said that a back-to-back spike within 24 hours typically signals that a larger move is underway.&nbsp;<stembedurl>https://stocktwits.com/Enjoiskating1216/message/621091545</stembedurl>Another expressed confidence in a major upside, suggesting the stock could revisit the $50 mark.<stembedurl>https://stocktwits.com/BestNwest/message/621099818</stembedurl>Nuwellis’ stock has declined 86.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nuwellis (NUWE) was granted a new U.S. Patent for innovations in blood filtering machine design. (Photo credit: Getty Images)

Nuwellis Stock Rises After Hours Following Patent Win For Blood Filtering System — Retail Mood Turns Buoyant

The patent for its blood filtering technology aims to improve fluid balance accuracy in CRRT by accounting for actual fluid density instead of relying on standard assumptions.

Nuwellis, Inc. (NUWE) Reports Q1 Loss, Lags Revenue Estimates

CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates

Shares of medical device company Nuwellis Inc. ($NUWE) more than doubled on Monday afternoon following its announcement that the Centers for Medicare and Medicaid Services (CMS) will significantly hike the reimbursement levels for its ultrafiltration therapy, lifting retail sentiment. Effective January 1, 2025, the reimbursement payment rate for the Minneapolis-based company’s Aquadex SmartFlow therapy, used for treating fluid overload in heart failure patients, will increase from $413 to $1,639 per day, a major step for the company’s outpatient therapy.&nbsp; Stocktwits users celebrated the move, suggesting the stock should go much higher following the news.&nbsp; &nbsp;<stembedurl>https://stocktwits.com/xpb199/message/591140624</stembedurl><stembedurl>https://stocktwits.com/Rampageusa/message/591116254</stembedurl> &nbsp;"This change underscores the clinical importance and cost-effectiveness of our ultrafiltration technology and will expand patient access to this life-saving therapy,” Nestor Jaramillo, President and CEO of Nuwellis, said in a statement. “It is well understood that providing care in an outpatient setting can be a better means to manage disease and prevent costly emergency hospitalizations.”&nbsp; The move will help expand the therapy’s reach to more patients on the sub-acute or chronic disease management program.Nuvellis plans to report its <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketwatch.com/story/nuwellis-shares-surge-following-preliminary-3q-results-c5fa917d">third-quarter</a> results and host its earnings conference call on November 11. The company said recently it is expecting to report revenue of $2.4 million, in line with the year-ago period.Nuwellis shares rallied over 106% today, but the stock is down roughly 88% year-to-date. Still, the stock is seeing a major jump in activity among retail investors and traders, with today’s symbol page views on Stocktwits hitting more than 25x their average over their one-month average.For updates and corrections, email newsroom@stocktwits.com

Shares of medical device company Nuwellis Inc. ($NUWE) more than doubled on Monday afternoon| Image source: Pixabay

Nuwellis Stock Spikes After Reimbursement Hike: Retail’s Upbeat

Effective January 1, 2025, the payment rate for its Aquadex SmartFlow therapy, used for treating fluid overload in heart failure patients, will increase 397% from $413 to $1,639 per day.

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Nuwellis Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $COIN earnings on Thursday?

Current Price	$2.33
Prev Close	$2.21
Open	$2.33
Dividend Yield	0.00%
50-Day Moving Average	$2.41
Beta	1.15
Avg. Volume	6.35M
PE Ratio	-0.02

52-Week High	$62.16
52-Week Low	$1.71
Market Capitalization	$4.14M
EPS (Annual)	-$336.19
Price to Book	0.77
Revenue Per Employee	$230,000.00

NUWE
Nuwellis Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NUWE News

NUWENuwellis Inc